FDA approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation. This first drug in its class (IDH1 inhibitors) is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
